{"id":793509,"date":"2024-12-09T16:08:29","date_gmt":"2024-12-09T21:08:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-to-present-new-data-at-san-antonio-breast-cancer-symposium\/"},"modified":"2024-12-09T16:08:29","modified_gmt":"2024-12-09T21:08:29","slug":"myriad-genetics-to-present-new-data-at-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-to-present-new-data-at-san-antonio-breast-cancer-symposium\/","title":{"rendered":"Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium"},"content":{"rendered":"

\nPresentations include analytical validation of Myriad\u2019s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk\u00ae with RiskScore\u00ae
\n<\/h2>\n
\n

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc<\/u><\/a>. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium\u00ae <\/sup>(SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries.<\/p>\n

Additional new data will show how Myriad\u2019s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection.<\/p>\n

\u201cWe are very excited to share validation data of our MRD assay. SABCS gives us the opportunity to showcase our clinical expertise in the prevention and treatment of early and advanced breast cancer,\u201d said George Daneker, MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. \u201cMyriad is one of the only labs that can offer germline and tumor genomic testing, combined with customizable workflow solutions and point-of-care patient education sessions. Our test results are supported by treatment-focused reporting, concordance checks between germline and tumor genomic results, and a summary sheet designed to help oncologists and breast surgeons interpret actionable insights more effectively.\u201d<\/p>\n

\n Myriad Genetics Data Presentations<\/strong>\n <\/p>\n

\n Spotlight Presentation:<\/strong> Session 16, PS16-01: Polygenic Risk
Date:<\/strong> Thursday, Dec. 12, 2024, 5:30-7:00 pm (CST), Hemisfair Ballroom 3
Presenter:<\/strong> Timothy Simmons, PhD, Biostatistician III, Myriad Genetics
The presentation will share longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors.<\/p>\n

\n Rapid-Fire Presentation:<\/strong> RF1-06
Date:<\/strong> Wednesday, Dec. 11, 2024, 12:00-12:50 pm (CST), Hall 1
Presenter: <\/strong>Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics
Dr. Johansen Taber will share data detailing the association of polygenic-based breast cancer risk prediction with patient management.<\/p>\n

\n Poster Presentation:<\/strong> P2-04-23
Date:<\/strong> Wednesday, Dec. 11, 2024, 5:30-7:00 pm (CST), Halls 2-3
Presenter:<\/strong> Ashley Acevedo, PhD, Staff Computational Scientist, Myriad Genetics
This poster shares the analytical validation of a high-definition tumor-informed Molecular Residual Disease (MRD) assay to demonstrate robust detection at low-tumor fractions, which are common in breast cancer.<\/p>\n

\n Poster Presentation:<\/strong> P3-02-10
Date:<\/strong> Thursday, Dec. 12, 2024, 12:30-2:00 pm (CST), Halls 2-3
Presenter:<\/strong> Holly Pederson, MD, Cleveland Clinic
Dr. Pederson will share her evaluation of a polygenic risk score as a predictor of breast cancer, triple-negative breast cancer, and early-onset disease in Hispanic women.<\/p>\n

In addition to data presentations, Myriad will welcome attendees to its booth (#1327) during exhibition hours. Among the Myriad products highlighted in the company\u2019s SABCS exhibit are:<\/p>\n